Patients with severe type 2 diabetes (T2D) and obesity exhibit duodenal dysfunction and morphologic changes, similar to ones described above, along with altered glucose absorption physiology leading to enhanced blood glucose, insulin, and glucagon and decreased glucagon-like peptide–1 (GLP-1) (2, 3). The gene discussed is GCG; the disease is obesity disorder.